197 results on '"Höiom, Veronica"'
Search Results
2. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
3. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in CDKN2A and Pancreatic Cancer
4. BAP1 genetic testing among melanoma and cancer-prone families in Sweden
5. Familial features affecting the melanoma risk in CDKN2A-negative melanoma families: a study based on the Swedish Cancer Registry.
6. Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
7. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations
8. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma
9. Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
10. BAP1 genetic testing among melanoma and cancer-prone families in Sweden
11. Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma
12. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations
13. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status
14. Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
15. Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
16. Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma
17. Whole-Exome Sequencing of Germline Variants in Non-BRCA Families with Hereditary Breast Cancer
18. Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
19. Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
20. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies
21. The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length
22. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma
23. Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions
24. CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020: implications for novel national recommendations
25. Additional file 1 of Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
26. Additional file 2 of Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
27. CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015–2020 : implications for novel national recommendations
28. Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families
29. Inherited variation in the PARP1 gene and survival from melanoma
30. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families
31. An inherited variant in the gene coding for vitamin D-binding protein and survival from cutaneous melanoma: a BioGenoMEL study
32. Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
33. Inherited variants in the MC1R gene and survival from cutaneous melanoma: a BioGenoMEL study
34. Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study
35. MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
36. A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma.
37. Publisher Correction: Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways
38. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT
39. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT
40. Novel loss-of-function variant in DENND5Aimpedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
41. Comprehensive Study of the Clinical Phenotype of GermlineBAP1Variant-Carrying Families Worldwide
42. Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study.
43. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
44. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations.
45. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations
46. CM-Score: a validated scoring system to predict CDKN2A germline mutations in melanoma families from Northern Europe
47. Phenocopies in melanoma-prone families with germ-line CDKN2A mutations
48. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
49. Germline Variation at CDKN2A and Associations with Nevus Phenotypes among Members of Melanoma Families
50. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.